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Despite their differential cell tropisms, HIV-1 and HCV dramatically inﬂuence disease progression in
coinfected patients. Macrophages are important target cells of HIV-1. We hypothesized that secreted
HCV core protein might modulate HIV-1 replication. We demonstrate that HCV core signiﬁcantly
enhances HIV-1 replication in human macrophages by upregulating TNF-a and IL-6 via TLR2-,
JNK-, and MEK1/2-dependent pathways. Furthermore, we show that TNF-a and IL-6 secreted from
HCV core-treated macrophages reactivates monocytic U1 cells latently infected with HIV-1. Our
studies reveal a previously unrecognized role of HCV core by enhancing HIV-1 infection in
macrophages.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.+1. Introduction
Increased progression rates to acquired immunodeﬁciency syn-
drome (AIDS) and liver disease have been reported in individuals
coinfected with human immunodeﬁciency virus type 1 (HIV-1)and hepatitis C virus (HCV) [1,2]. Strikingly, activation of CD4 T
cells, macrophages, and dendritic cells enhances HIV-1 viral repli-
cation [3–6]. In HIV-1-infected individuals, higher viral loads and
faster progression to AIDS correlate with systemic markers of
immune activation [7]. Furthermore, cells latently infected by
HIV-1 serve as long-lasting viral reservoirs and hinder the eradica-
tion of HIV-1 from infected patients with antiretroviral treatment.
HCV infection causes chronic inﬂammation of the liver and
affects 3% of the human population worldwide [8]. The molecular
mechanism(s) underlying uncontrolled, chronic liver inﬂammation
remain poorly understood but may include direct viral effects and
immune activation and dysregulation.
Combined immune dysregulation, immune deﬁciency, and
immune activation have been proposed to worsen disease progres-
sion in HIV-1/HCV-coinfected patients [9]. The inﬂuence of HCV on
HIV-1 infection remains poorly understood [10,11]. HIV-1 infection
of macrophages plays a key role in viral pathogenesis, allowing
accumulating replication-competent HIV-1, even in patients
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supporting HCV infection of macrophages in vivo [13,14], the abil-
ity of macrophages to support productive HCV infection remains
controversial ([15], and recently reviewed in [16]). In addition,
HIV has been shown to facilitate HCV infection of native human
macrophages in vitro [17]. Macrophage phagocytic uptake of HCV
triggers immune activation [18], suggesting their contribution to
chronic inﬂammation in infected individuals. Even though these
viruses infect distinct cell types, a potential mechanism of interac-
tion between HIV-1 and HCV is through the action of viral secreted
proteins that takes place during viral replication.
HCV core is a secreted viral protein that has been detected in
the circulation of HCV-infected patients [19]. Although several
HCV proteins exhibit immunomodulatory activity, HCV core is
unique in its pleiotropic effects [20]. In addition to its structural
role in the encapsidation of the viral RNA, HCV core exhibits
multiple regulatory functions, including the induction of tumori-
genesis, regulation of viral and cellular gene expression, modula-
tion of apoptosis, and suppression of host immunity [21–24]. The
potential contribution of HCV core to HIV pathogenesis remains
poorly understood. HCV core has been shown to mediate repres-
sion of the HIV-1 protein Tat-mediated transactivation of HIV-1
long terminal repeat (LTR) in a hepatoma cell line [25]. In contrast,
Khan et al [26] have shown that HCV core and HIV-1 protein Nef
upregulated HIV-1 LTR-driven luciferase expression in a
transiently-transfected human monocytic cell line. Strikingly, the
potential role of HCV core on HIV-1 infectivity in the context of
infection, rather than plasmid-based transcription analysis,
remains unknown.
Tumor necrosis factor (TNF-a) and interleukin-6 (IL-6) are key
proinﬂammatory cytokines known to enhance HIV-1 replication
[27–30]. Interestingly, stimulation of naïve, uninfected human
macrophages with HCV core induces TNF-a and IL-6 production
through a Toll-like receptor 2 (TLR2)-mediated pathway [31].
Because HCV core has been shown to both inhibit and enhance
HIV-1 transcription [25,26,32], and the impact of HCV core on HIV-
1 infection in macrophages is not well known, we aimed to deter-
mine the effect of HCV core stimulation in HIV-1 infection of THP-1
promonocytic cells, primary monocyte-derived macrophages
(MDMs), and in the HIV-1 latently-infected U1 monocytic cell line.
We found that HCV core mediates enhancement of HIV-1 infection
in macrophages through a TLR2-, JNK-, and MEK1/2-mediated
pathway that results in upregulation of TNF-a and IL-6 as ﬁnal
molecular effectors. Our study identiﬁes a novel role of HCV
core-TLR2 interaction in augmenting HIV-1 infection in macro-
phages and reactivation of HIV-1-infected latent reservoirs.
2. Materials and methods
2.1. Ethics statement
De-identiﬁed human monocytes from healthy blood donors
were obtained from the University of Pennsylvania’s Human
Immunology Core (operating under the supervision of the Univer-
sity of Pennsylvania’s Institutional Review Board). We did not have
any interaction with human subjects or protected information, and
therefore no informed consent was required. All studies were
approved and supervised by Drexel University’s Institutional
Review Board.
2.2. Cell culture
A promonocytic cell line (THP-1) was differentiated in RPMI
1640 medium containing 10% heat-inactivated fetal bovine serum
(hiFBS) certiﬁed for low endotoxin and hemoglobin levels
(BenchMark FBS, Gemini Bio-Products, West Sacramento, CA),100 ng/ml of phorbol 12-myristate 13-acetate (PMA), antibiotics,
and l-glutamine for 3 days. Cells rested in media containing no
PMA for 3 more days to obtain macrophages (referred to as THP-
1 macrophages). Primary MDMs were generated by culturing
human monocytes in Dulbecco’s modiﬁed Eagle’s Medium
(DMEM) supplemented with 10% hiFBS, antibiotics, and 16 U/ml
macrophage colony-stimulating factor (eBioscience, San Diego,
CA) for 7 days. Human embryonic kidney (HEK) 293T cells were
cultured in DMEM supplemented with 10% DFBS and antibiotics.
The HIV-1 latently-infected U1 monocytic cell line was obtained
through the AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH from Dr. Thomas Folks. These cells
were cultured in RPMI 1640 medium containing 10% hiFBS and
L-glutamine. All experiments involving U1 cells were performed
in a biosafety level 3 laboratory under standard operating
procedures. All cells were maintained at 37 C with 5% CO2.
2.3. Single-cycle HIV-1 BaL infection assay
Single-round infectious, luciferase-reporter HIV-1 BAL pseudo-
typed virions were produced by cotransfecting HEK 293T cells
and normalized by p24 as previously described [33]. Infectivity
was measured by luciferase activity in cell lysates using a micro-
plate luminometer (GloMax, Promega, Madison, WI).
2.4. Stimulation of macrophages with recombinant HCV core and
b-galactosidase proteins
THP-1 macrophages and MDMs were treated with either 5 lg/
ml of recombinant HCV core protein genotype 1b fused to b-galac-
tosidase (Virogen, Watertown, MA), or 5 lg/ml of b-galactosidase
(b-Gal) control protein (Virogen). THP-1 and MDMs were ﬁrst
infected with HIV-1 BAL pseudovirus and treated with either b-
Gal or HCV core recombinant proteins at 14 h after infection.
HIV-1-infected, HCV core-stimulated macrophages were incubated
at 37 C for 48 h; supernatants were collected for assessing cyto-
kine production and cells were lysed to determine HIV-1 infectivity
by luciferase activity (Promega).
2.5. Pharmacological inhibition of MAP kinases
THP-1 macrophages and human primary MDMs were treated
with JNK [50 lM SP600125 (Invivogen, San Diego, CA)], p38
[20 lM SB203580 (Invivogen)], and MEK1/2 [50 lM PD98059
and 10 lM U0126 (both from Cell Signaling, Danvers, MA)] kinase
inhibitors. To evaluate effects of MAP kinase inhibitors on HCV
core-mediated induction of HIV-1 infectivity, macrophages were
prestimulated with the inhibitors as above, then infected with
HIV-1 BAL for 12 h (in the presence or absence of these inhibitors)
and treated with b-Gal or HCV core proteins, and ﬁnally lysed to
determine luciferase activity 48 h after infection. To deﬁne the
effects of the MAP kinase inhibitors on HCV core-mediated induc-
tion of TNF-a and IL-6 in uninfected macrophages, cells were stim-
ulated with MAP kinase inhibitors for 1 h before exposure to HCV
core or b-Gal, and during stimulation for 14 h. Supernatants were
collected and assayed by ELISA to determine cytokine induction.
2.6. Neutralization of TLR2, TNF-a, and IL-6
To determine the role of TLR2 in HCV core-mediated stimula-
tion of uninfected macrophages, cells were prestimulated with
10 lg/ml of a TLR2 neutralizing antibody (nAb) (Invivogen) for
1 h and then treated with 5 lg/ml of HCV core and 5 lg/ml of
b-Gal as a negative control, in the continuous presence of the
nAb. To determine the role of TLR2 in HCV core-mediated enhance-
ment of HIV-1 infectivity in THP-1 macrophages and primary
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hours after infection, cells were treated with 10 lg/ml of the
TLR2 nAb for 1 h. We next treated the cells with 5 lg/ml of HCV
core, and 5 lg/ml of b-Gal as a negative control, in the continuous
presence of the nAb. Macrophages were lysed 48 h after infection
and tested for HIV-1 infection.
THP-1 macrophages and primary MDMs were infected with
HIV-1 BAL pseudovirus and treated with 5 lg/ml of b-Gal or
5 lg/ml of HCV core, in the presence or absence of 20 lg/ml of
an anti-TNF-a nAb (Thermo Fisher Scientiﬁc, Rockford, IL) and/
or 20 lg/ml of an anti-IL-6 nAb (Thermo Fisher). Supernatants
were collected for measuring cytokine production (ELISA) 48 h
after incubation, and cells were lysed to measure HIV-1 BaL
infection.
2.7. TNF-a and IL-6 determination by ELISA
Supernatants were analyzed for secretion of proinﬂammatory
cytokines TNF-a and IL-6 using commercial ELISA kits (eBio-
science). Limit of detection of TNF-a and IL-6 ELISAs are 0.13 and
0.03 pg/ml, respectively.
2.8. Western blotting assays
Western blot analysis was performed in unstimulated and HCV
core-stimulated THP-1 differentiated macrophages. Cells were
stimulated with 5.0 lg/ml HCV core or b-Gal protein control for
20 and 60 min. Cells were washed with ice-cold PBS and then
lysed. Whole-cell lysates (35 lg) were mixed with Laemmli load-
ing buffer containing b-mercaptoethanol and heated at 95 C for
5 min. The samples were loaded onto 10% precast polyacrylamide
gels (Bio-Rad, Hercules, CA) and electrophoresis was performed
at 90 V for 90 min. Proteins were transferred onto methanol-
activated PVDF membranes (EMD Millipore, Billerica, MA) by
wet-transfer system (Bio-Rad) at 100 V for 60 min. Membranes
were blocked in LI-COR Odyssey blocking buffer (LI-COR, Lincoln,
NE) for 1 h and scanned with the LI-COR Odyssey IR imager using
appropriate secondary antibodies coupled to IR680 or IR800 dye.
All primary antibodies used were purchased from Cell Signalling
Technology (Beverly, MA); anti-p-ERK1/2 (1:500), anti-ERK1/2
(1:500), anti-SAPK/JNK (1:1000), anti-p-SAPK/JNK (1:1000),
anti-p38 MAPK (1:500), anti-p-p38 MAPK (1:500), and anti-
HSP90 (1:5000) as endogenous control.
2.9. HIV-1 latency reactivation and macrophage-conditioned media
experiments
U1 cells were directly treated with 5 lg/ml of b-Gal, or 5 lg/ml
HCV core, or 100 ng/ml of PMA (as a TLR2-independent positive
control for HIV-1 reactivation) for 14 h. Cells were next centrifuged
and supernatants collected. For macrophage-conditioned media
(CM) experiments, U1 cells were treated with supernatants from
macrophages that were either unstimulated or stimulated with
b-Gal or HCV core, either individually or in the presence of neutral-
izing TNF-a antibody, neutralizing IL-6 antibody, or both. U1 cells
were centrifuged and supernatants were collected 14 h after
stimulation with CM. Reactivation of the latent HIV-1 in U1 cells
was determined using a commercial HIV-1 p24 ELISA (ABL,
Rockville, MD HIV p24 ELISA; limit of detection is 3.1 pg/ml).
2.10. Statistical analysis
Statistical signiﬁcance of experimental data was determined by
unpaired Student’s t-test and P < 0.05 was considered statistically
signiﬁcant.3. Results
3.1. HCV core enhances HIV-1 infection of THP-1 cells and primary
macrophages
We investigated the potential effects of HCV core in HIV-1
infectivity in THP-1 cells and in primary MDMs. For this purpose,
we used a single-round infectious, luciferase-reporter HIV-1
pseudotype that express the envelope of CCR5-using, macro-
phage-tropic BaL [33,34]. Using this system, LTR-driven luciferase
expression is a measure of HIV-1 infection. We performed a dose
response curve to investigate the effects of HCV core on differenti-
ated, HIV-1-infected THP-1 cells. For all our experiments we used
an HCV genotype 1b recombinant core protein fused to b-galacto-
sidase simultaneously, or b-Gal protein alone as a negative control.
The use of these HCV core and b-Gal recombinant proteins has
been previously established and a dose of 5 lg/ml has been deter-
mined to exhibit various effects on different cell types [35,36]. We
then investigated the effects of 0.1, 0.5, 1.0, 2.5, and 5.0 lg/ml of
HCV core or b-Gal protein. After differentiation, THP-1 cells were
infected with HIV-1 BaL pseudovirus for 12 h and treated with
HCV core protein or b-Gal protein alone as a negative control; lucif-
erase was measured 48 h after HIV-1 infection. As shown in Fig. 1A,
HCV core concentrations below 2.5 lg/ml did not affect HIV-1
infectivity. In contrast, stimulation of infected THP-1 cells with
2.5 lg/ml or 5.0 lg/ml HCV core signiﬁcantly increased LTR-driven
luciferase expression (P < 0.001), suggesting that HCV core can
enhance HIV-1 replication in infected macrophages. As expected,
treatment with b-Gal protein did not affect HIV-1 infectivity
(Fig. 1A).
To determine the kinetics of HCV core-mediated enhancement
of HIV-1 infection in macrophages, we performed time course
experiments. We found that THP-1 macrophages treated with
HCV core at the time of infection or at 4 h post-infection showed
no signiﬁcant change in HIV-1 infectivity compared with
untreated, or b-Gal-treated, HIV-1-infected cells (Fig. 1B). Interest-
ingly, stimulation of THP-1 macrophages with HCV core at 8, 12
and 24 h post-infection signiﬁcantly increased LTR-driven lucifer-
ase expression (8 h p.i., P < 0.05; and 12 and 24 h p.i., P < 0.01).
These ﬁndings suggest that HCV core-mediated enhancement of
HIV-1 infection in macrophages occurs when entry and early
post-entry events have been completed.
To determine that HCV core increases HIV-1 infection in pri-
mary human macrophages, we stimulated MDMs with 5.0 lg/ml
of HCV core or b-Gal protein control 12 h after HIV-1 BaL infection.
As shown in Fig. 1C, HCV core induced a signiﬁcant upregulation of
LTR-driven luciferase expression in HIV-1 infected MDMs (Fig. 1C,
P < 0.05). Taken together, these results suggested that HCV core
stimulation after HIV-1 infection of macrophages enhances HIV-1
replication.
3.2. HCV core enhances HIV-1 infectivity in macrophages via a TLR2-,
JNK-, and MEK1/2-dependent pathway
Previous studies have demonstrated that HCV core but not HCV
virion can trigger TLR2-mediated pathways [31,36–38]. To deter-
mine the role of TLR2 in HCV core-mediated enhancement of
HIV-1 infectivity in macrophages, we used a nAb against TLR2.
Twelve hours after HIV-1 BaL infection, THP-1 macrophages and
primary MDMs were treated with HCV core, or b-Gal protein, in
the presence or the absence of anti-TLR2 nAb. Strikingly, blocking
TLR2 abrogated HCV core enhancement of HIV-1 replication
(Fig. 2A and B).
MAP kinases play a prominent role as molecular mediators of
TLR-induced inﬂammation, and as critical regulators of
Fig. 1. HCV core enhances HIV-1 BaL infection of THP-1 macrophages and MDMs.
(A) HCV core dose curve experiment. THP-1 differentiated cells were stimulated
with 0.1, 0.5, 1.0, 2.5, and 5 lg/ml of HCV core, or b-Gal recombinant protein control
at 12 h after infection with a luc-reporter, macrophage-tropic BaL HIV-1 pseudo-
type. (B) HCV core time course experiment. THP-1 differentiated cells were
stimulated with 5 lg/ml of HCV core, or b-Gal recombinant protein control at the
time of infection (time 0) and 4, 8, 12, and 24 h after HIV-1 BaL infection. (C)
Primary human macrophages (MDMs) were stimulated with 5 lg/ml of HCV core,
or b-Gal recombinant protein control at 12 h after HIV-1 BaL infection. LTR-driven
Luciferase activity was measured 2 days after infection and results from 5
independent experiments (THP-1) and 2 independent MDMs donors are shown.
Luciferase activity in cell lysates was measured as relative light units per second.
Data are shown as percent luciferase expression relative to HIV-1 infected alone
cells (mean ± SD). Values that were signiﬁcantly different (P < 0.05) from the value
of HIV-infection alone group are indicated (*).
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we investigated the involvement of the c-Jun aminoterminal
kinase (JNK), the p38 MAP kinases (p38), and the extracellular sig-
nal-regulated protein kinase 1/2 (ERK) in HCV core-mediated
enhancement of HIV-1 infectivity in macrophages. None of the
MAP kinase inhibitors tested affected HIV-1 infectivity in macro-
phages (white bars in Fig. 2C and D). In contrast, pharmacological
inhibition of JNK (SP600125) and MEK1/2 (U0126) signiﬁcantly
reduced HCV core enhancement of HIV-1 infectivity (P < 0.05) in
THP-1 and MDMs (Fig. 2C and D). A signiﬁcant difference was
observed after inhibition of p38 MAPK (SB203580) in THP-1 cells.Although HCV core effect was reduced in MDMs, the difference
was not statistically signiﬁcant (Fig. 2C and D). Since U0126 is a
highly selective inhibitor of both MEK1 and 2, we investigated
the effects of another MEK1/2 inhibitor (PD98059) that inhibits
MEK1 more potently than MEK2. In contrast to the signiﬁcant
effect of U0126, we found that PD98059 only partially reduced
HCV core enhancement of HIV-1 infection (Fig. 2C and D). These
data suggest that MEK1 and MEK2 have differential contributions
to HCV core effect (being more dependent on MEK2 than MEK1),
or that both MEK1 and MEK 2 are equally required. Taken together,
our data demonstrated that HCV core promotes HIV-1 infectivity in
macrophages via a TLR2- JNK- MEK1/2-dependent pathway.
Furthermore, our data suggest differential activation/regulation
of p38 kinase in THP-1 and MDMs.
To investigate a potential direct role of HCV core on MAP
kinases stimulation in macrophages, we stimulated differentiated
THP-1 cells with 5.0 g/ml of HCV core and b-Gal as a negative con-
trol. Because we aimed to elucidate direct effects of HCV core stim-
ulation on MAP kinases, we stimulated cells using short times of
incubation (20 and 60 min). Twenty minutes was selected because
there is previous data in the literature demonstrating that HCV
core activates ERK1/2 phosphorylation in human monocytes at this
short time after stimulation [31]. As shown in Supplementary
Fig. 1A, we observed a twofold induction of ERK1/2 phosphoryla-
tion after stimulation with 5.0 lg/ml HCV core for 20 min. Pharma-
cological inhibition of ERK1/2 (PD98059, UO126) in HCV core-
stimulated cells reduced ERK1/2 phosphorylation to levels below
those observed in unstimulated cells, whereas SP600125 (a JNK
inhibitor) exhibited only a slight reduction on HCV core-mediated
ERK1/2 phosphorylation (Supplementary Fig. 1A). Interestingly, we
observed a stimulatory effect of SB203580 (p38 kinase inhibitor)
on ERK1/2 phosphorylation that has been previously noted in other
cell types (Supplementary Fig. 1A) [40]. It should be noted that a
dominant negative mutant of p38 also increased ERK1/2 phosphor-
ylation in response to UVA [41]. Therefore, it is unlikely that the
effects on ERK1/2 are due to non-selectivity of SB203580 p38
inhibitor. Indeed, a crosstalk between ERK1/2 and p38 kinases
has been previously demonstrated in various cell types, and usu-
ally these kinases have opposing effects. Interestingly, p38 exhibits
a negative regulation on the ERK pathway in response to redox and
mitogen stimulation with PMA in various cell types [40,42]. In
addition, HCV core stimulation activated p38 kinase phosphoryla-
tion, but it did not affect JNK after 20 min of HCV core stimulation.
Similar results were obtained 60 min after stimulation (data not
shown). b-Gal protein did not affect kinase activation (data not
shown). Taken together, these data demonstrated that HCV core
stimulation directly activates pathways that mediate rapid phos-
phorylation of ERK1/2 and p38 kinases shortly after stimulation
of macrophages.
3.3. Role of TNF-a and IL-6 in HCV core enhancement of HIV-1
infectivity in macrophages
The proinﬂammatory cytokines IL-6 and TNF-a upregulate
production of HIV-1 in acutely as well as in chronically infected
cells of monocytic lineage [43]. Furthermore, extracellular HCV
core induces secretion of proinﬂammatory cytokines, including
TNF-a and IL-6 in antigen-presenting cells (APCs) [35,44,45]. Thus,
we investigated the role of TNF-a and IL-6 in HCV core-mediated
upregulation of HIV-1 infectivity in macrophages. As shown in
Fig. 3A and B, stimulation with HCV core induced TNF-a and IL-6
production in uninfected macrophages. While HIV-1 BaL infection
or HCV core stimulation alone resulted in secretion of these cyto-
kines, treatment of macrophages with HCV core after HIV-1 BaL
infection resulted in signiﬁcant overproduction of both TNF-a
and IL-6. To determine whether TNF-a and/or IL-6 contribute to
Fig. 2. HCV core enhances HIV-1 infectivity via TLR2. THP-1 macrophages (A) and MDMs (B) were infected with a luc-reporter, macrophage-tropic BaL HIV-1 pseudotype.
Cells were unstimulated or stimulated with 5 lg/ml of HCV core or b-Gal recombinant protein control in the presence of a neutralizing human monoclonal anti-TLR2 Ab or
isotype control (Invivogen) 12 h after infection. Luc activity was measured 2 days after infection and results from 3 independent experiments (THP-1) and 2 independent
MDMs donors are shown. Luciferase activity in cell lysates was measured as relative light units per second. Results represent means ± SD. To determine the role of MAP
kinases in HCV core-mediated enhancement of HIV infection in THP-1 macrophages (C) and MDMs (D), cells were prestimulated with speciﬁc inhibitors of JNK (50 lM
SP600125), p38 (20 lM SB203580), and MEK1/2 (50 lM PD98059, and 20 lM U0126) for 30 min and then infected with HIV-1 BaL pseudotype. Infected cells were left
unstimulated or treated with HCV core or b-Gal 12 h after infection. Luc activity was measured 2 days after infection and results from 3 independent experiments (THP-1) and
2 independent MDM donors are shown. Luciferase activity in cell lysates was measured as relative light units per second. Data are shown as relative luciferase units (RLU) of
HIV infectivity (mean ± SD). Values that were signiﬁcantly different (P < 0.05) from the value of HIV-infection alone group are indicated (*).
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BaL-infected THP-1 macrophages and MDMs with HCV core in
the presence or absence of nAbs against TNF-a and IL-6. Blockade
of TNF-a suppressed HCV core-mediated enhancement of HIV-1
infectivity whereas blocking IL-6 partially prevented this effect
(Fig. 3C and D). Simultaneous blockade of TNF-a and IL-6 signiﬁ-
cantly abrogated HCV core-mediated enhancement of HIV-1 infec-
tivity. These ﬁndings demonstrate that TNF-a and to a lesser extent
IL-6, mediated HCV core enhancement of HIV-1 infectivity in
macrophages.
3.4. Role of MAP kinases in HCV core induction of TNF-a and IL-6 in
macrophages
Our data demonstrated the involvement of JNK and MEK1/2
kinases in the TLR2-mediated, HCV core enhancement of HIV-1
infectivity in THP-1 macrophages and MDMs (Fig. 2C and D). Thus
we investigated whether MAP kinases play a role in HCV core-
mediated induction of TNF-a and IL-6 in THP-1 macrophages and
primary MDMs. Production of TNF-a by HCV core was signiﬁcantly
reduced by SP600125, SB203580, and U0126, whereas the effect of
PD98059 did not reach statistical signiﬁcance (Fig. 4A). These ﬁnd-
ings conﬁrmed the differential contribution of JNK, MEK1/2, and
p38 MAP kinases in HCV core-mediated TNF-a production in unin-
fected macrophages. Importantly, these ﬁndings correlated withinhibition of HIV-1 BaL infectivity in HCV core-stimulated THP-1
macrophages (Fig. 2C). In addition, although SP600125,
SB203580, U0126, and PD98059 inhibitors signiﬁcantly affected
HCV core-mediated IL-6 production, only SP600125 and U0126
suppressed IL-6, suggesting a prominent role of JNK and MEK1/2
kinases in HCV core-mediated IL-6 induction in THP-1 macro-
phages (Fig. 4B).
Our data show that in primary MDMs only SP600125 and
U0126 inhibitors signiﬁcantly reduced HCV core-mediated
enhancement of HIV-1 infectivity (Fig. 2D). Interestingly,
SP600125 and U0126 signiﬁcantly inhibited both TNF-a and IL-6
production in HCV core-stimulated MDMs, suggesting that JNK
and MEK1/2 kinases play a key role in HCV core induction of both
cytokines in primary MDMs. In contrast, no signiﬁcant changes
were observed with SB203580 and PD98059 inhibitors, in parallel
with results demonstrating a lack of effect of these inhibitors in
HCV core enhancement of HIV-1 infectivity in MDMs (Fig. 2D).
Overall, these ﬁndings suggest that JNK and MEK1/2 kinases
contribute to TNF-a and IL-6 production in HCV core-stimulated
THP-1 macrophages and primary MDMs. In contrast, pharmacolog-
ical inhibition of p38 MAP kinase with SB203580 signiﬁcantly
reduced HCV core induction of TNF-a and IL-6 in THP-1 macro-
phages, with no effects in primary MDMs. Importantly, these ﬁnd-
ings correlate with the effects of these MAP kinase inhibitors in
HCV core enhancement of HIV-1 infectivity (Fig. 2C and D).
Fig. 3. HCV core-induced TNF-a and IL-6 mediate the enhancement of HIV-1 infection in THP-1 macrophages and MDMs. (A) TNF-a and (B) IL-6 cytokine induction in naïve,
HIV-BaL-infected, and/or stimulated with HCV core, and b-galactosidase protein control was measured by ELISA. (C) THP-1 macrophages and (D) MDMs were infected with
HIV-BaL for 12 h. Cells were left unstimulated or treated with HCV core, or b-galactosidase protein control, in the presence or absence of speciﬁc human monoclonal nAbs
anti-TNF-a and/or anti-IL-6. HIV infectivity was determined by luciferase activity in cell lysates 48 h after infection. Data are shown as relative fold induction of HIV
infectivity (mean ± SD). Results from 3 independent experiments (THP-1) and 2 independent MDM donors are shown. ⁄Signiﬁcantly different (P < 0.05) from the HIV-infection
alone group.
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infected U1 cells
U1 is a cell line derived from U937 promonocytic cells latently
infected with HIV-1 that has been established as a model for HIV-1
latency [46]. Although provirus expression in U1 cells is poor (at
least in part due to a defective Tat function [47,48]), HIV-1 provirus
expression is highly inducible following treatments with various
cytokines or phorbol esters [46,49]. Therefore, we next investi-
gated the effects of HCV core protein on HIV-1 reactivation in U1
cells. Unexpectedly, stimulation of U1 cells with HCV core did
not affect HIV-1 latency (Fig. 5A), similarly to b-Gal negative con-
trol. In contrast, PMA induced robust upregulation of HIV-1 p24
(Fig. 5A), demonstrating that U1 cells are responsive to phorbol
esters, as expected. Although HCV core stimulation of U1 cells
did not directly reactivate HIV-1, we next examined the hypothesis
that TNF-a and IL-6 induced in HCV core-stimulated macrophages
might reactivate HIV-1 in U1 cells. To test this hypothesis we ﬁrst
stimulated U1 cells with conditioned media (CM) of THP-1 macro-
phages and primary MDMs that have been stimulated with HCV
core or the b-Gal control. Stimulation of U1 cells with CM of HCV
core-treated THP-1 macrophages and MDMs induced HIV-1 reacti-
vation similarly to PMA treatment alone (Fig. 5A and C). Strikingly,
neutralization of TNF-a and/or IL-6 reduced HIV p24 induction in
U1 cells stimulated with CM of HCV core-treated macrophages.
The contribution of TNF-a to HIV-1 reactivation in CM-stimulated
U1 cells was more profound than that of IL-6. Taken together, these
ﬁndings suggested that although HCV core lacks the ability todirectly reactivate HIV-1 in latently-infected U1 cells, CM of HCV
core-stimulated macrophages induced HIV-1 reactivation in U1
cells through TNF-a and IL-6.
Finally, in order to understand the inability of HCV core to
directly reactivate HIV-1 in U1 cells, we determined TNF-a induc-
tion in U1 cells stimulated with HCV core, b-Gal, and various TLR2
agonists [FSL-1, PAM3CSK4, and heat-killed Listeria monocytoge-
nes (HKLM)], or PMA (as a positive control of TLR2-independent
activation). Ligand recognition and signaling through TLR2 occurs
via heterodimerization with TLR1 or TLR6. In the absence of TLR1
and TLR6, TLR2 homodimerization has been proposed, but it
remains to be fully demonstrated [50]. Interestingly, stimulation
with FSL-1 (TLR2/TLR6) and HKLM (proposed TLR2/TLR2) agonists
did not induce TNF-a production in U1 cells. In contrast, both PMA
and the TLR2/TLR1 agonist PAM3CSK4 induced robust upregula-
tion of TNF-a in U1 cells (Fig. 5B). These ﬁndings demonstrate that
TLR2 heterodimerization with TLR1 is functional in U1 cells. In
contrast, stimulation of TLR2 heterodimerization with TLR6, or
TLR2/TLR2 homodimerization with FSL-1 and HKLM, respectively,
failed to activate U1 cells. Taken together, these data suggest that
the absence of functional TLR2/TLR6 heterodimerization or TLR2/
TLR2 homodimerization may account for the inability of HCV core
to stimulate U1 cells.
4. Discussion
HCV-associated liver disease is accelerated in HIV-1-infected
individuals, and several mechanisms have been proposed [11,51].
Fig. 4. TNF-a and IL-6 cytokine induction mediated by HCV core is dependent on MAP kinases. THP-1 macrophages (A and B) and MDMs (C and D) were stimulated with HCV
core or b-galactosidase protein control in the presence or absence of 50 lM SP600125 (JNK inhibitor), 20 lM SB203580 (p38 inhibitor), 50 lM PD98059 (MEK1/2 inhibitor),
and 10 lMU0126 (MEK1/2 inhibitor). TNF-a (A and C) and IL-6 (B and D) induction was determined by ELISA (R&D Systems, Minneapolis, MN) 14 h after stimulation. Results
from 3 independent experiments (THP-1) and 2 independent MDM donors are shown. Data are means ± SD. ⁄Signiﬁcantly different (P < 0.05) from HCV core-stimulated
group.
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potential contribution of HCV core to HIV pathogenesis is emerg-
ing. Because of their differential tropism, it is tempting to speculate
that HCV core, the only known HCV protein that is secreted into
the blood of infected individuals, may impact HIV-1 infectivity of
macrophages.
Here we investigated the impact of HCV core protein on acute
and latently HIV-infected macrophages. Our ﬁndings demonstrate
that HCV core stimulation of HIV-1 acutely infected THP-1 macro-
phages and primary MDMs induced enhancement of HIV-1 infec-
tivity through a mechanism that is dependent on TLR2, JNK, and
MEK1/2 kinases. In addition, we have identiﬁed TNF-a and, to a
lesser extent, IL-6 as ﬁnal molecular effectors in this pathway. Fur-
thermore, using the promonocytic U1 cell line as a model system
for HIV-1 latency, we have shown that conditioned media from
THP-1 macrophages and primary MDMs stimulated with HCV core
signiﬁcantly upregulated HIV-1 production in U1 cells through a
TNF-a and IL-6-dependent mechanism. Intriguingly, HCV core
direct stimulation of U1 cells failed to directly reactivate latent
HIV-1 infection, at least in part because of the lack of functional
TLR2/TLR6 heterodimerization or TLR2/TLR2 homodimerization in
U1 cells.It is well established that systemic markers of immune activa-
tion are associated with higher HIV-1 viral loads and faster pro-
gression to AIDS [52]. The effects of various TLR agonists and
microbial components of frequent opportunistic infections such
as Mycobacterium spp., Neisseria gonorrhoeae, and others, in acute
and latently infected HIV-1 cell cultures, and in a few in vivo mod-
els, have been previously reported [53–56]. In particular, TLR2 has
been implicated in enhancing susceptibility to HIV infection of
Langerhans cells and naïve and memory CD4+ T cells [57–62], reac-
tivation of latently infected central memory CD4+ T cells [63], as
well as reducing susceptibility of macrophages to HIV-1 infection
[64]. Interestingly, we have found that HCV core-induced enhance-
ment of HIV-1 infectivity in THP-1 macrophages and primary
MDMs is dependent on TLR2 (Fig. 2A and B). Our ﬁndings are in
agreement with previous data demonstrating that HCV core
triggers TLR2-mediated pathways in macrophages [31]. Using
pharmacological inhibitors of JNK, p38, and MEK1/2 MAP kinases,
we identiﬁed a key role of JNK and MEK1/2 kinases in HCV core
enhancement of HIV-1 infection in THP-1 and primary MDMs
(Fig. 2C and D). Importantly, treatment with kinase inhibitors alone
did not affect HIV-1 infection. We have investigated the effects of
HCV core in differentiated THP-1 cells in the absence of HIV-1
Fig. 5. HCV core and conditioned media (CM) of HCV core-stimulated THP-1 macrophages and MDMs differentially affect reactivation of HIV-1 latent infection in U1 cells. (A)
HCV core does not induce p24 production in U1 cells. U1 cells were stimulated with HCV core, b-galactosidase (negative control), or PMA (positive control) for 12 h.
Supernatants of stimulated U1 cells were assayed for p24 secretion by ELISA 24 h after stimulation. (B) U1 cells show differential TNF-a production in response to TLR2/6 and
TLR2/1 agonists. U1 cells were stimulated with PMA (positive control), HCV core, b-galactosidase protein, TLR2/6 agonist FSL-1, TLR2/1 agonist PAM3CSK4, and TLR2/2 agonist
HKLM for 12 h. Supernatants of stimulated U1 cells were assayed for p24 production by ELISA 24 h after stimulation. (C) Stimulation of U1 cells with CM of HCV core-
stimulated THP-1 macrophages and MDMs induced signiﬁcant p24 production through the induction of the proinﬂammatory cytokines TNF-a and IL-6. U1 cells were
stimulated with supernatants of HCV core-stimulated THP-1 macrophages and MDMs collected 14 h after stimulation (CMs). Supernatants from U1 cells stimulated with CMs
were assayed for p24 production by ELISA 24 h after stimulation. Results from 3 independent experiments (THP-1 and U1) and CMs of 2 independent MDM donors are shown.
Data are mean ± SD; ⁄signiﬁcantly different (P < 0.05) from control.
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tion of MAP kinases in response to HCV core stimulation, our data
demonstrates that HCV core stimulation induces rapid phosphory-
lation of ERK1/2 and p38 kinases. However we did not observed
phosphorylation of JNK at 20 or 60 min after stimulation suggest-
ing that HCV core may mediate JNK phosphorylation at later times
after stimulation, or that its phosphorylation is mediated indirectly
by the production of pro-inﬂammatory cytokines, likely TNF-a that
is known to induce transient and sustained activation of JNK [65].
It is important to note that HIV-1 infection alone may affect MAP
kinases activation, and that synergistic, additive or antagonistic
mechanisms may regulate the precise role of ERK1/2, p38, and
JNK kinases in HIV-1-infected macrophages that are stimulated
with HCV core. Further investigations will deﬁne their speciﬁc
roles in HCV core-mediated enhancement of HIV-1 infectivity in
macrophages.
Proinﬂammatory cytokines such as TNF-a and IL-6 can enhance
HIV-1 infection and replication [43]. We found that HCV core stim-
ulation induced both cytokines in uninfected macrophages (Fig. 3A
and B). Furthermore, THP-1 macrophages and primary MDMs trea-
ted with HCV core after HIV-1 infection produced signiﬁcantly
higher TNF-a and IL-6 compared with HIV-1-infected, unstimu-
lated cells. Using nAbs anti-TNF-a, and anti-IL-6, we demonstratethat HCV core’s pro-HIV-1 effect is mediated by TNF-a and, to a les-
ser extent, IL-6 induction.
Stimulation of macrophages by TLR ligands leads to the activa-
tion of MAP kinases and the subsequent induction of cytokine gene
expression. Our data demonstrate that HCV core-mediated induc-
tion of TNF-a and IL-6 in THP-1 macrophages and in primary
MDMs is signiﬁcantly reduced in the presence of SP600125, and
U0126 (Fig. 4C and D). Taken together with the effects of these
inhibitors on HCV core enhancement of HIV-1 infection (Fig. 2C
and D), our data suggest that JNK and MEK1/2 play key roles in
HCV core-induced upregulation of HIV-1 infection through the
induction of TNF-a and IL-6 in macrophages. Inhibition of p38
kinase with SB203580 signiﬁcantly reduced TNF-a and IL-6 in
THP-1 macrophages, but not in MDMs (Fig. 4). These data correlate
with the lack of inhibitory effect of SB203580 on HCV core
enhancement of HIV-1 infection in MDMs (Fig. 2D) compared with
the reduction in THP-1 macrophages (Fig. 2C).
To investigate the potential effects of HCV core stimulation on
HIV-1 latently infected monocytic cells, we used the U1 cell line.
Surprisingly, HCV core failed to induce upregulation of latent
HIV-1 in U1 cells (Fig. 5A). However, conditioned media (CM) of
HCV core-stimulated THP-1 macrophages and primary MDMs
induced profound HIV-1 reactivation through the induction of
G. Swaminathan et al. / FEBS Letters 588 (2014) 3501–3510 3509TNF-a and IL-6 (Fig. 5B). Although our goal was not to investigate
potential effects of TLR agonists on HIV-1 infection, we provide evi-
dence that the latently HIV-1-infected promonocytic U1 cell line is
responsive to a TLR2/1 agonist (PAM3CSK4), but fails to be stimu-
lated by a TLR2/6 agonist (FSL-1). These data are in agreement with
recent ﬁndings demonstrating that PAM3CSK4, but not FSL-1 ago-
nist, reactivates HIV-1 latent infection in U1 cells and in latently
infected central memory T cells and resting CD4+ T cells from avire-
mic patients [63]. Because PAM3CSK4 reactivated latent HIV-1 in
the absence of T cell activation or proliferation, these authors sug-
gested that further investigation of the TLR1/2 pathway may lead
to the identiﬁcation of agonists that like PAM3CSK4 have the
potential to be explored as antilatency drugs. Our ﬁndings demon-
strate that TLR2 heterodimerization with TLR1 is functional in U1
cells. In contrast, activation of TLR2 heterodimerization with
TLR6 (FSL-1) or TLR2/TLR2 homodimerization (HKLM) failed to
activate U1 cells. It has been previously shown that TNF-a and
IL-6 induced after stimulation with HCV core in primary MDMs
are dependent on TLR2 heterodimerization with both TLR1 and
TLR6 [45]. Taken together, these data suggest that the absence of
functional TLR2/TLR6 heterodimerization may account for the
inability of HCV core to stimulate U1 cells.
Overall, these studies identify a novel role of HCV core in
augmenting acute, and latent HIV-1 infection in macrophages, with
implications towards a better understanding of the inter-
inﬂuential role of HIV-1 and HCV in coinfected patients.
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